Adds details in paragraphs 3, 4 and 5
April 25 (Reuters) - Eli Lilly LLY.N has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said on Friday.
Last month, the regulator had rejected the drug, Kisunla, saying that the treatment's ability to slow cognitive decline was not large enough to outweigh the risk of serious brain swelling in patients.
Lilly had said at the time that it planned to seek a re-examination from the regulator.
Upon receiving the grounds of the request, the agency said it will reconsider its opinion and issue a final recommendation for the drug.
Lilly's drug is already approved in the United States.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Saumyadeb Chakrabarty)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。